PDF(Pubmed)
Abstract：
Hepatitis C virus (HCV) can cause a range of kidney diseases. HCV is the primary cause of mixed cryoglobulinaemia, which leads to cryoglobulinaemic vasculitis and cryoglobulinaemic glomerulonephritis (GN). Patients with acute cryoglobulinaemic vasculitis often exhibit acute kidney disease due to HCV infection, which typically progresses to acute kidney injury (AKI). HCV also increases the risk of chronic kidney disease (CKD) and the likelihood of developing end-stage renal disease (ESRD). Currently, direct-acting antiviral agents (DAAs) can be used to treat kidney disease at different stages. This review focuses on key findings regarding HCV and kidney disease, discusses the impact of DAAs, and highlights the need for further research and treatment.
摘要：
丙型肝炎病毒（HCV）可导致一系列肾脏疾病。HCV是混合型冷球蛋白血症的主要原因,导致冷球蛋白血症性血管炎和冷球蛋白血症性肾小球肾炎（GN）。急性冷球蛋白血症性血管炎患者常表现为HCV感染引起的急性肾脏疾病，通常进展为急性肾损伤（AKI）。HCV还增加慢性肾病(CKD)的风险和发展为终末期肾病(ESRD)的可能性。目前,直接作用抗病毒药物（DAA）可用于治疗不同阶段的肾脏疾病。这篇综述的重点是关于HCV和肾脏疾病的关键发现。讨论DAAs的影响，并强调需要进一步研究和治疗。
